Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
AMGN stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Amgen Inc. stock logo

Amgen Inc.

AMGN·NASDAQ

Last updated as of 2026-02-10 21:56 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

AMGN stock price change

On the last trading day, AMGN stock closed at 368.26 USD, with a price change of -2.01% for the day.
Trade stock futures

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

AMGN key data

Previous close368.26 USD
Market cap198.30B USD
Volume422.78K
P/E ratio25.88
Dividend yield (TTM)2.53%
Dividend amount2.38 USD
Last ex-dividend dateNov 21, 2025
Last payment dateDec 12, 2025
EPS diluted (TTM)14.23 USD
Net income (FY)7.71B USD
Revenue (FY)36.75B USD
Next report dateApr 29, 2026
EPS estimate4.830 USD
Revenue estimate-
Shares float537.39M
Beta (1Y)0.22
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Amgen Inc. overview

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Sector
Health technology
Industry
Biotechnology
CEO
Robert A. Bradway
Headquarters
Thousand Oaks
Website
amgen.com
Founded
1980
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-

AMGN Pulse

Daily updates on AMGN stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• AMGN Stock Price 24h change: +4.49%. From 367.80 USD to 384.32 USD. This surge was primarily driven by a "beat-and-raise" fourth-quarter earnings report, where revenues grew 9% to $9.9 billion and adjusted EPS of $5.29 exceeded expectations, alongside optimistic 2026 guidance and confidence in the MariTide weight-loss pipeline.
• From a technical perspective, AMGN is in a "Strong Bullish Breakout" phase, recently hitting a fresh 52-week high of $385.12. Key indicators show the stock is trading well above its 50-day ($335.30) and 200-day ($302.96) moving averages; however, an RSI of 75.56 suggests it is currently in overbought territory and may face short-term consolidation near the $385 resistance level.
• Amgen reported Q4 revenues of $9.9 billion, a 9% year-over-year increase, driven by double-digit volume growth in key drugs like Repatha and Evenity.
• The company issued 2026 revenue guidance of $37 billion to $38.4 billion and raised its quarterly dividend by 6% to $2.52 per share.
• Goldman Sachs raised its price target for AMGN to $415, citing high confidence in the long-term potential of its experimental obesity drug, MariTide, currently in Phase 3 trials.
• Eli Lilly (LLY) announced a $2.4 billion acquisition of Orna Therapeutics to expand its presence in the "in vivo" CAR-T cell therapy space, signaling continued consolidation in high-growth biotech sectors.
• The FDA launched a new "PreCheck" pilot program aimed at accelerating the construction and regulatory review of domestic drug manufacturing facilities to strengthen the U.S. medicine supply chain.
See more
about 1D ago
• AMGN Stock Price 24h change: +4.49%. From 367.80 USD to 384.32 USD. The surge was driven by a fourth-quarter "beat and raise" earnings report and positive Phase 2 trial data for its obesity drug, MariTide.
• Technical Indicators: RSI (14) is at 69.00 (approaching overbought), MACD is 5.77 (Sell), and the 200-day SMA is 299.20 (Buy). The stock is in a strong short-term uptrend, having broken out of an ascending triangle, but may face resistance near its all-time high of $385.
• Amgen reported Q4 2025 revenue of $9.87 billion, exceeding the $9.47 billion estimate, and raised its 2026 revenue guidance to a range of $37 billion to $38.4 billion.
• Clinical data for MariTide showed up to 20% weight loss over 52 weeks with monthly or quarterly dosing, positioning it as a significant competitor in the obesity market.
• Goldman Sachs raised its price target for AMGN to $415 from $403, maintaining a "Buy" rating based on strong portfolio momentum and the obesity drug pipeline.
• The U.S. FDA launched the "PreCheck" pilot program to accelerate the construction and review of domestic drug manufacturing facilities to strengthen the medical supply chain.
• Pfizer and Merck released Q4 earnings highlighting a strategic focus on oncology and obesity, while the sector saw increased M&A activity interest in AI-focused biotech firms.
See more
about 2D ago

AMGN stock price forecast

According to technical indicators for AMGN stock, the price is likely to fluctuate within the range of 352.22–449.28 USD over the next week. Market analysts predict that the price of AMGN stock will likely fluctuate within the range of 334.15–545.45 USD over the next months.

Based on 1-year price forecasts from 79 analysts, the highest estimate is 552.29 USD, while the lowest estimate is 281.17 USD.

For more information, please see the AMGN stock price forecast Stock Price Forecast page.

Latest AMGN stock news

Stocks Remain Close to All-Time Highs Amid Mixed Economic Data from the US

101 finance2026-01-07 19:33:30

Concerned About the K-Shaped Economic Recovery? Consider Investing in This Leading Dividend ETF for 2026.

101 finance2026-01-08 00:03:30

Stocks End Mostly Down After Initial Gains Disappear

101 finance2026-01-08 00:45:31

AbbVie secures agreement with the Trump administration on medication pricing in return for tariff reductions

101 finance2026-01-13 09:24:29

Factbox-Global drugmakers rush to boost US presence as tariff threat looms

101 finance2026-01-13 13:21:24

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

101 finance2026-01-15 12:24:24

Kailera’s Ron Renaud discusses how a startup with connections to China can stand out in the obesity market

101 finance2026-01-20 12:09:29

What’s Ahead in the Markets This Week: January Employment Data; Earnings Releases from Alphabet, Amazon, AMD, Disney, and Palantir

101 finance2026-02-01 11:06:48

January employment report, Alphabet and Amazon financial results, further impact from Warsh: Key events to follow this week

101 finance2026-02-01 12:51:28

Amgen (AMGN) Q4 Preview: Key Insights Before Earnings Release

101 finance2026-02-02 03:18:33

Amgen quarterly results beat Street estimates on higher sales, lower tax rate

101 finance2026-02-03 21:09:09

Amgen's Q4 results beat expectations, continues to advance clinical research on next-generation weight loss drugs

格隆汇2026-02-04 02:20:30

The three major U.S. stock indexes closed mixed, with AMD down over 17%.

格隆汇2026-02-04 22:10:00

Biogen (BIIB) Q4 Preview: Key Information Before Earnings Release

101 finance2026-02-05 03:15:40

The Top 5 Analyst Questions That Stood Out During Amgen’s Q4 Earnings Call

101 finance2026-02-10 10:45:14

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Amgen Inc.?

AMGN is currently priced at 368.26 USD — its price has changed by -2.01% over the past 24 hours. You can track the stock price performance of Amgen Inc. more closely on the price chart at the top of this page.

What is the stock ticker of Amgen Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ, Amgen Inc. is traded under the ticker AMGN.

What is the stock forecast of AMGN?

We've gathered analysts' opinions on Amgen Inc.'s future price. According to their forecasts, AMGN has a maximum estimate of 3682.60 USD and a minimum estimate of 736.52 USD.

What is the market cap of Amgen Inc.?

Amgen Inc. has a market capitalization of 198.30B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
AMGN